معرفی
Mario Kahn is a Researcher in the Department of Internal Medicine Endocrinology at Yale School of Medicine. His research focuses on metabolic dysfunction-associated diseases, lipid metabolism, and insulin resistance mechanisms. Collaborators include renowned scientists like Gerald I. Shulman and Varman Samuel. Recent work examines liver lipid droplet cholesterol's role in non-alcoholic steatohepatitis (NASH), SGLT2 inhibitor effects on cardiac metabolism, and bioactive lipid changes post-weight loss in diabetes. Key findings include mechanistic insights into PKCε-mediated insulin resistance and calcium-regulated hepatic gluconeogenesis. Kahn’s studies often utilize rodent models and human clinical data to bridge molecular mechanisms with clinical implications.
Education & Affiliations:
- Yale School of Medicine (Primary affiliation)
Research Interests:
- Metabolic disorders, particularly NASH and diabetes
- Lipid signaling in insulin resistance
- Organelle cross-talk in metabolic diseases
- Drug mechanisms in metabolic pathways
Recent Publications Trends: Recent articles emphasize mitochondrial dysfunction, lipid droplet biology, and systemic metabolic interactions. Key themes include drug target validation (e.g., SGLT2 inhibitors), enzyme deficiency models (e.g., AGPAT2), and biomarker discovery for metabolic diseases.
Awards & Grants: No specific awards or grants listed in available texts.
Advising & Teams: Collaborates with multidisciplinary teams but no formal student advising roles explicitly noted. Active in lab environments focused on metabolic disease research.
Labs/Teams: Part of Yale’s Metabolic Research Group, collaborating with departments like Molecular Virology and Cardiology to integrate lipid metabolism studies with clinical outcomes.